We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Instem Plc | AQSE:INS.GB | Aquis Stock Exchange | Ordinary Share | GB00B3TQCK30 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMINS
Instem plc
09 January 2017
9 January 2017
Instem plc
("Instem" or the "Company" or the "Group")
Appointment of Chief Operating Officer
Instem (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces the appointment of Ms. MaryBeth Thompson as Chief Operating Officer of the Group with immediate effect. Ms. Thompson, who has not been appointed to the Instem plc main Board, will report to Phil Reason, CEO.
Ms. Thompson has more than 18 years of experience in the life sciences industry, with a primary focus in Regulatory Affairs and Operations with a demonstrable track record as a leader and builder of outsourcing services businesses.
During her tenure at PAREXEL International ("PAREXEL"), a multinational life sciences consulting firm, and its predecessor organisations LIQUENT and CDC Solutions, she established and expanded the regulatory outsourcing services practice from a $1 million revenue business with 30 employees to an international organisation across the US, Europe and India with more than $30 million of revenues and 300 employees.
Prior to PAREXEL, Ms. Thompson worked for AstraZeneca and Wyeth-Ayerst Laboratories in pharmaceutical product development, where she held a range of senior regulatory positions.
Phil Reason, CEO of Instem, commented: "We are delighted to have appointed someone of MaryBeth's calibre and experience to Instem. MaryBeth has a strong track record in building life sciences businesses and we look forward to the benefits she will bring as we embark upon the Company's next phase of growth."
For further information, please contact:
Instem plc +44 (0) 1785 825 600 Phil Reason, CEO Nigel Goldsmith, CFO N+1 Singer (Nominated Adviser & Broker) +44 (0) 20 7496 3000 Richard Lindley Nick Owen Walbrook Financial PR +44 (0) 20 7933 8000 Paul Cornelius instem@walbrookpr.com Helen Cresswell Sam Allen Paul Whittington
About Instem
About Instem plc
Instem is a leading supplier of IT applications and services to the early development healthcare market delivering compelling solutions for data collection, analysis and regulatory submissions management. Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.
To learn more about Instem solutions and its mission, please visit www.instem.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGUAPGUPMGCB
(END) Dow Jones Newswires
January 09, 2017 09:30 ET (14:30 GMT)
1 Year Instem Chart |
1 Month Instem Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions